Reactive Oxygen Species-Responsive Ferrocene Nanoparticles Delivering Small Interfering RNA Targeting NOP2/Sun RNA

Yunsheng Lu1, Yibin Huang1, Chenchen Mao2

  • 1Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

PubMed

Insights

A novel nanoparticle (PRPFc@siNSUN2) delivers siNSUN2 to gastric cancer cells, utilizing tumor microenvironment conditions to release the therapeutic agent. This approach enhances anti-cancer effects and improves patient outcomes.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Silencing NSUN2 inhibits gastric cancer (GC) progression, but delivery challenges like degradation and low uptake limit its efficacy.
  • The tumor microenvironment's high reactive oxygen species (ROS) levels present a therapeutic opportunity.

Purpose of the Study:

  • To design and synthesize a novel ROS-responsive ferrocene nanoparticle (PRPFc@siNSUN2) for targeted delivery of siNSUN2 in GC.
  • To evaluate the nanoparticle's characteristics, ROS responsiveness, and therapeutic efficacy in vitro and in vivo.

Main Methods:

  • Synthesis and characterization of PRPFc@siNSUN2 using techniques like NMR, TEM, DLS, and UV-Vis spectrophotometry.
  • Assessment of ROS-triggered siNSUN2 release and nanoparticle stability under varying conditions.
  • In vitro evaluation of GC cell proliferation, migration, invasion, and apoptosis.
  • In vivo studies to confirm therapeutic efficacy, cytotoxicity, and biocompatibility.

Main Results:

  • PRPFc@siNSUN2 is a spherical nanoparticle (88.79 nm) with high encapsulation efficiency (83.10%) and drug loading (13.85%).
  • The nanoparticles demonstrated excellent stability and significant siNSUN2 release in response to ROS (H2O2).
  • In vitro, PRPFc@siNSUN2 effectively inhibited GC cell proliferation, migration, and invasion, promoting apoptosis and increasing ROS levels.
  • In vivo studies confirmed enhanced therapeutic efficacy of siNSUN2 against GC with low cytotoxicity and good biocompatibility.

Conclusions:

  • PRPFc@siNSUN2 nanoparticles offer a promising strategy for ROS-triggered delivery of siNSUN2, improving anti-gastric cancer effects.
  • The developed nanoparticle system enhances siNSUN2 uptake and therapeutic outcomes by targeting the tumor microenvironment.
  • NSUN2 is a viable therapeutic target, and PRPFc@siNSUN2 nanoparticles show potential for improving clinical treatment of GC.